Illumina's Q3 Revenues Increase 5 Percent; Shares Plunge on Estimate Miss

Illumina missed analysts' consensus estimate, and its shares plunged in after-hours trade. The shortfall was due to a few issues, including a quality control issue related to sequencing reagent kits that could impact Illumina's Q4 revenues as well.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories